EUVIMEDEUVIMED entdecken
Multizentrische StudieEvaluationsstudieOpen Access · CC BY 4.0

High-throughput multiplex detection of respiratory pathogens: multicenter evaluation of the NxTAG Respiratory Pathogen Panel v2 assay

Marisa C Nielsen iD, Ping Ren iD, Sri Bharathi Kavuri, Karissa Culbreath iD, Rangaraj Selvarangan iD, Dithi Banerjee iD, Blake W Buchan iD, Rachel Behounek iD, Janet Farhang iD

Journal of Clinical Microbiology · 2026

DOI: 10.1128/jcm.01743-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Microbiology, 2026. Verfasst von Marisa C Nielsen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pathology and Laboratory Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Respiratory Tract Infections, Molecular Diagnostic Techniques, Viruses, Bacteria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Respiratory tract infections remain a major cause of global morbidity, highlighting the need for rapid and accurate diagnostic testing. This multicenter study evaluated the clinical and analytical performance of the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput multiplex molecular assay designed to detect 21 viral and bacterial respiratory pathogens. A total of 2,145 nasopharyngeal swab specimens, including both prospectively enrolled and archived specimens, were analyzed across five U.S. clinical sites. The NxTAG RPPv2 was assessed against FDA-cleared molecular assays and bi-directional sequencing, with contrived specimens used to supplement low-prevalence targets. Valid results were obtained for 99.7% of specimens after a single retest, with minimal performance differences between fresh and frozen specimens. Among viral targets, 15 of 18 (one viral target did not have clinical positive specimens for analysis) achieved ≥95% positive percent agreement (PPA) across the prospective and pre-selected arms. For bacterial targets, Mycoplasma pneumoniae and Chlamydia pneumoniae showed PPA values of 92.3% and 100%, respectively. Lower PPA values were observed for parainfluenza 4 (90.3%). Negative percent agreement (NPA) was consistently high across targets, with all viral and bacterial analytes achieving ≥99.2%. Reproducibility across sites and operators was 99.9%. Overall, the NxTAG RPPv2 demonstrated high accuracy, reproducibility, and operational efficiency, supporting its clinical utility for rapid and reliable diagnosis of respiratory tract infections. IMPORTANCE Respiratory infections remain a major global health challenge, particularly during seasonal epidemics and pandemics. Rapid and accurate pathogen detection is essential to guide treatment decisions, limit transmission, and reduce unnecessary antibiotic use. This multicenter study evaluated the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput molecular assay capable of detecting 22 common viral and bacterial respiratory pathogens from a single sample. The panel demonstrated high accuracy, reproducibility, and reliability across multiple clinical sites and sample types, including both fresh and frozen specimens. These findings support the NxTAG RPPv2 as a comprehensive, efficient diagnostic tool that can support respiratory infection diagnosis and contribute to multifaceted antimicrobial stewardship efforts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Respiratory Tract InfectionsMolecular Diagnostic TechniquesVirusesBacteriaMultiplex Polymerase Chain ReactionBacterial InfectionsVirus DiseasesHigh-Throughput Screening AssaysHumansSensitivity and SpecificityProspective StudiesUnited StatesNasopharynxChild, PreschoolChildFemaleReproducibility of ResultsInfantMale

Stichwörter der Autor:innen

molecular diagnosticsmultiplex PCRrespiratory tract infectionssyndromic testing

Autor:innen und Institutionen

  • Pathology and Laboratory Medicine, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Department of Pathology, University of Texas Medical Branch, Galveston, Texas, USA.
  • TriCore Reference Laboratories, Albuquerque, New Mexico, USA.
  • Children's Mercy Kansas City, Kansas City, Missouri, USA.
  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Luminex Corporation, Austin, Texas, USA.

ORCID-Profile: Marisa C Nielsen, Ping Ren, Karissa Culbreath, Rangaraj Selvarangan, Dithi Banerjee, Blake W Buchan, Rachel Behounek, Janet Farhang

Zitieren

APA

Nielsen, M. C., Ren, P., Kavuri, S. B., Culbreath, K., Selvarangan, R., Banerjee, D., Buchan, B. W., Behounek, R., & Farhang, J. (2026). High-throughput multiplex detection of respiratory pathogens: multicenter evaluation of the NxTAG Respiratory Pathogen Panel v2 assay. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.01743-25

Vancouver

Nielsen MC, Ren P, Kavuri SB, Culbreath K, Selvarangan R, Banerjee D, et al. High-throughput multiplex detection of respiratory pathogens: multicenter evaluation of the NxTAG Respiratory Pathogen Panel v2 assay. Journal of Clinical Microbiology. 2026. doi:10.1128/jcm.01743-25

BibTeX
@article{Nielsen2026,
  author = {Nielsen, Marisa C and Ren, Ping and Kavuri, Sri Bharathi and Culbreath, Karissa and Selvarangan, Rangaraj and Banerjee, Dithi and Buchan, Blake W and Behounek, Rachel and Farhang, Janet},
  title = {High-throughput multiplex detection of respiratory pathogens: multicenter evaluation of the NxTAG Respiratory Pathogen Panel v2 assay},
  journal = {Journal of Clinical Microbiology},
  year = {2026},
  doi = {10.1128/jcm.01743-25}
}
Kostenlos starten →